Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2015 4
2016 4
2017 3
2018 5
2019 12
2020 4
2021 8
2022 4
2023 7
2024 12
2025 20
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martínez López J, Rodríguez-Otero P, Dytfeld D, Jakubowiak A, Schinke C, Besemer B, Anguille S, Manier S, Rasche L, Teipel R, Scheid C, Pawlyn C, Cavo M, Diels J, Ghilotti F, Lau BW, Renaud T, Orel O, Ong F, Ramos DF, Ammann E, Parekh T, Albrecht C, Weisel K, Mateos MV. Einsele H, et al. Among authors: vincent l. Adv Ther. 2026 Jan;43(1):333-355. doi: 10.1007/s12325-025-03409-y. Epub 2025 Nov 28. Adv Ther. 2026. PMID: 41313549 Free PMC article.
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.
Moreau P, Hulin C, Talbot A, Demarquette H, Caillot L, Chalopin T, Bobin A, Manier S, Leleu X, Karlin L, Caillot D, Sonntag C, Feugier P, Roussel M, Gounot R, Macro M, Mohty M, Garderet L, Tiab M, Orsini-Piocelle F, Vincent L, Meuleman N, Fontan J, Montes L, Vekemans MC, Escoffre-Barbe M, Eveillard JR, Schiano de Colella JM, Lambert J, Mary JY, Fermand JP, Arnulf B, Corre J, Avet-Loiseau H, Facon T, Harousseau JL, Touzeau C, Perrot A. Moreau P, et al. Among authors: vincent l. Blood Cancer J. 2025 Oct 24;15(1):177. doi: 10.1038/s41408-025-01387-6. Blood Cancer J. 2025. PMID: 41136366 Free PMC article. Review.
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study.
Chalopin T, Cellerin E, Demarquette H, Pieragostini A, Sonntag C, Jaquet C, De Wyngaert Z, Rumpler A, Roussel M, Labouré G, Morel V, Vincent L, Salle V, Cazaubiel T, Bobin A, Schavgoulidze A, Corre J, Leleu X, Manier S. Chalopin T, et al. Among authors: vincent l. Blood Cancer J. 2025 Oct 21;15(1):174. doi: 10.1038/s41408-025-01365-y. Blood Cancer J. 2025. PMID: 41120261 Free PMC article. No abstract available.
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study.
Cazaubiel T, Decaux O, Royer B, Caillot D, Bobin A, Belhadj-Merzoug K, Macro M, Vincent L, Perrot A, Mohty M, Karlin L, Jacquet C, Frenzel L, Chalopin T, Sonntag C, Fontan J, Rigaudeau S, Touzeau C, Demarquette H, Chaib A, Santana C, Darre S, Bareau B, Garlantézec R, Hulin C. Cazaubiel T, et al. Among authors: vincent l. Clin Hematol Int. 2025 Sep 18;7(3):60-68. doi: 10.46989/001c.143641. eCollection 2025. Clin Hematol Int. 2025. PMID: 40978559 Free PMC article.
Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort.
Hulin C, Belhadj Merzoug K, Royer B, Caillot D, Bobin A, Macro M, Karlin L, Mohty M, Frenzel L, Perrot A, Vincent L, Dib M, Piocell FO, Benramdane R, Calmettes C, Chalopin T, Garlantézec R, Désaméricq G, Mechiche H, Decaux O. Hulin C, et al. Among authors: vincent l. Clin Lymphoma Myeloma Leuk. 2026 Jan;26(1):e1-e11.e4. doi: 10.1016/j.clml.2025.08.002. Epub 2025 Aug 7. Clin Lymphoma Myeloma Leuk. 2026. PMID: 40967989 Free article.
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.
Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M, Malard F, Petillon MO, Manier S, Yakoub-Agha I, Caillot D, Lafon I, Leleu X, Moya N, Royer B, Schiano De Colella JM, Brisou G, Touzeau C, Perrot A, Bories P, Vincent L, Guedon H, Decaux O, Ferment B, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Avet-Loiseau H, Moreau P, Arnulf B. Cayla S, et al. Among authors: vincent l. Blood Adv. 2026 Feb 24;10(4):1324-1333. doi: 10.1182/bloodadvances.2025017597. Blood Adv. 2026. PMID: 40966637 Free PMC article.
Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study.
Chalopin T, Hulin C, Royer B, Bastie JN, Bobin A, Merzoug KB, Macro M, Karlin L, Jacquet C, Mohty M, Frenzel L, Sonntag C, Fontan J, Rigaudeau S, Roussel M, Sanhes L, Chaoui D, Vincent L, Orfeuvre H, Bouketouche M, Garlantezec R, Decaux O, Perrot A. Chalopin T, et al. Among authors: vincent l. Haematologica. 2026 Feb 1;111(2):728-732. doi: 10.3324/haematol.2025.287954. Epub 2025 Aug 28. Haematologica. 2026. PMID: 40874328 Free PMC article. No abstract available.
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study.
Chalopin T, Decaux O, Hulin C, Perrot A, Macro M, Royer B, Bastie JN, Bobin A, Jacquet C, Mohty M, Frenzel L, Sonntag C, Roussel M, Sanhes L, Chaoui D, Dib M, Slama B, Richez V, Montes L, Dervite I, Laribi K, Re D, Garlantezec R, Merzoug KB, Vincent L. Chalopin T, et al. Among authors: vincent l. Clin Lymphoma Myeloma Leuk. 2025 Oct;25(10):759-762. doi: 10.1016/j.clml.2025.07.009. Epub 2025 Jul 24. Clin Lymphoma Myeloma Leuk. 2025. PMID: 40819983 No abstract available.
CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.
Chemlal D, Pochard C, Jacquier V, Bruyer A, Gabellier L, Fornero L, Vempère C, Machura A, Requirand G, Robert N, Bret C, Cartron G, Vincent L, de Boussac H, Moreaux J, Herbaux C. Chemlal D, et al. Among authors: vincent l. Oncoimmunology. 2025 Dec;14(1):2532226. doi: 10.1080/2162402X.2025.2532226. Epub 2025 Jul 20. Oncoimmunology. 2025. PMID: 40684280 Free PMC article.
76 results